NEW YORK (GenomeWeb News) – Celera Genomics today said it has received $900,000 from the US National Institutes of Health to develop and commercialize an in vitro diagnostic for detect the A/H5 influenza virus.
 
Celera said it plans to develop the test using the primer, probe set, and protocols used by US Health and Human Services' Centers for Disease Control and Prevention, whose IP was recently cleared by the US Food and Drug Administration.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.